摘要
目的对晚期宫颈癌患者应用白蛋白结合型紫杉醇治疗,评价治疗的临床疗效及安全性。方法选取我院2014年1月~2017年1月收治的40例晚期宫颈癌患者作为研究对象,按照电脑随机分组方法分为研究组(20例)与对照组(20例)。研究组患者采用白蛋白结合型紫杉醇化疗治疗,对照组患者采用紫杉醇化疗治疗。比较两组治疗后的瘤体最大直径、症状缓解时间、生活质量评分、临床缓解率和不良反应发生率。结果研究组患者的临床缓解率为95.00%,高于对照组(55.00%),差异有统计学意义(P<0.05);研究组患者治疗后瘤体最大直径、症状缓解时间和生活质量评分高于对照组,差异均有统计学意义(P<0.05);研究组患者的不良反应发生率低于对照组,差异有统计学意义(P<0.05)。结论对晚期宫颈癌患者应用白蛋白结合型紫杉醇治疗,具有一定药物安全性,能够大大提高患者的临床疗效。
Objective To evaluate the clinical efficacy and safety of albumin-bound paclitaxel in patients with advanced cervical cancer.Methods 40 patients with advanced cervical cancer who were treated in our hospital from January 2014 to January 2017 were selected as study subjects and divided into study group（20 cases） and control group（20 cases） by computer randomization method.The study group was adopted Albumin-bound paclitaxel chemotherapy treatment,the control group was used paclitaxel chemotherapy treatment.After treatment,the maximum diameter of tumor,symptom relief time,quality of life score,clinical remission rate and incidence of adverse reactions were compared between the two groups.Results The clinical remission rate of the study group was 95.00%,which was higher than that of the control group（55.00%）,the difference was statistically significant（P〈0.05）.The maximum diameter,symptom relief time and quality of life scores of the study group were higher than those of the control group.The differences were statistically significant（P〈0.05）.The incidence of adverse reactions in the study group was lower than that in the control group,the difference was statistically significant（P〈0.05）.Conclusion The application of albumin-bound paclitaxel to patients with advanced cervical cancer has certain drug safety and can greatly improve the clinical efficacy of the patients.
作者
赖宜段
LAI Yi-duan(Department of Gynecology and Obstetrics,Chaonan Minsheng Hospital of Shantou City,Guangdong Province,Shantou 515144,China)
出处
《中国当代医药》
2018年第11期66-68,共3页
China Modern Medicine
关键词
白蛋白结合型
紫杉醇
晚期宫颈癌
临床疗效
安全性
Albumin-binding
Paclitaxel
Advanced cervical cancer
Clinical efficacy
Safety
